Results 31 to 40 of about 1,157 (167)

In vitro assessment of recombinant, mutant immunoglobulin G anti-D devoid of hemolytic activity for treatment of ongoing hemolytic disease of the fetus and newborn [PDF]

open access: yes, 2008
A specific treatment for ongoing hemolytic disease of the fetus and newborn (HDFN) due to anti-D would be very attractive. One approach could be administration to the mother of nonhemolytic anti-D, which by crossing the placenta can block the binding of ...
Nielsen, Leif K   +6 more
core   +1 more source

Detection of anti-f on a 51-year-old Saudi female

open access: yesJournal of Applied Hematology, 2020
Anti-f/ce is a rare antibody but nevertheless associated with Hemolytic Disease of the Fetus and Newborn (HDFN) and Hemolytic Transfusion Reactions (HTR). This antibody shows reaction against products of the seemingly common R0 or r haplotypes.
Ahmed Alharbi   +5 more
doaj   +1 more source

Variations and opportunities in postnatal management of hemolytic disease of the fetus and newborn [PDF]

open access: yes
Importance: Preventive efforts in pregnancy-related alloimmunization have considerably decreased the prevalence of hemolytic disease of the fetus and newborn (HDFN).
David Mackin (17865761)   +4 more
core   +4 more sources

A case of naturally occurring anti-Dia antibody in a young man

open access: yesAsian Journal of Transfusion Science, 2022
The Diego (Di) blood group system comprises 22 antigens located on the band 3 protein, most of which are low-prevalence antigens. The majority of antibodies to Diego system antigens were of clinically insignificant; however anti-Dia, -Dib, -Wra, -ELO and-
Salfarina Iberahim   +12 more
doaj   +1 more source

Hemolytic disease of the fetus and newborn: rapid review of postnatal care and outcomes

open access: yesBMC Pregnancy and Childbirth, 2023
Background Advances in postnatal care for hemolytic disease of the fetus and newborn (HDFN) have occurred over the past decades, but little is known regarding the frequency of postnatal treatment and the clinical outcomes of affected neonates.
Derek P. de Winter   +4 more
doaj   +1 more source

A case report on non-D HDFN: Highlighting the role of antibody screening in RhD positive antenatal women

open access: yesAsian Journal of Transfusion Science, 2022
The widespread use of anti-D immunoglobulin has resulted in a relative increase in the importance of non-D alloimmunization as a cause of hemolytic disease of the fetus and newborn (HDFN).
Bharat Singh   +4 more
doaj   +1 more source

The unusual abundance of a rare finding!

open access: yesClinical Case Reports, 2019
We present images (Figure 1A‐D) of a preterm girl who had severe anemia due to HDFN caused by maternal anti‐C and anti‐D alloantibodies. These images show erythrophagocytosis, which is a very interesting and rarely encountered feature.
Rahaf Altahan, Areej Al Mugairi
doaj   +1 more source

Cold reacting anti‐M causing delayed hemolytic disease of the newborn [PDF]

open access: yes, 2019
BACKGROUND: Hemolytic disease of the fetus and newborn (HDFN) is due to passively transferred maternal antibodies directed against fetal red blood cell (RBC) antigens and can lead to severe morbidity and mortality.
Philip Crispin   +11 more
core   +1 more source

Not as “D”eadly as once thought – the risk of D-alloimmunization and hemolytic disease of the fetus and newborn following RhD-positive transfusion in trauma

open access: yesHematology, 2023
The use of blood products to resuscitate injured and massively bleeding patients in the prehospital and early in-hospital phase of the resuscitation is increasing.
Mark H. Yazer   +7 more
doaj   +1 more source

A rare case of immune hydrops in an “Elevated D” pregnancy

open access: yesGlobal Journal of Transfusion Medicine, 2020
The D-/-phenotype is a rare variant of the Rh system, in which red blood cells express only D antigen. Sensitized D-/-women carry a risk of hemolytic disease of fetus and newborn (HDFN) and pose a challenge in management due to nonavailability of antigen
Amit Kumar Biswas   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy